Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
The treatment effect of Infliximab on Spondyarthritis patients
View through CrossRef
Background: Biologic drugs, especially anti TNF-α drugs, are revolutionary in the treatment of Spondyloarthritis when the conventional DMARDs have proved ineffective.
Research objective: To evaluate the effectiveness of Infliximab treatment on Spondyloarthritis patients.
Materials and method: Longitudinal follow-up study with Infliximab treatment on 27 patients with Spondyloarthritis.
Results: The effectiveness of Infliximab on patients with Spondyloarthritis is demonstrated by clinical indicators; inflammatory markers: CRP, ESR in the first hour and the disease activity level according to ASDAS-CRP and ASDAS-ESR in the first hour at the time of T2, T6 compared to T0 were statistically significant (p < 0.05)). After excluding the data of 2 patients with flare at T14, all the above-mentioned indicators improved, the difference was statistically significant with p < 0.05.
Conclusion: Infliximab is effective in improving clinical symptoms, inflammatory markers and disease activity score in patients with Spondyloarthritis.
Key words: spondyloarthritis, Infliximab.
Hue University of Medicine and Pharmacy
Title: The treatment effect of Infliximab on Spondyarthritis patients
Description:
Background: Biologic drugs, especially anti TNF-α drugs, are revolutionary in the treatment of Spondyloarthritis when the conventional DMARDs have proved ineffective.
Research objective: To evaluate the effectiveness of Infliximab treatment on Spondyloarthritis patients.
Materials and method: Longitudinal follow-up study with Infliximab treatment on 27 patients with Spondyloarthritis.
Results: The effectiveness of Infliximab on patients with Spondyloarthritis is demonstrated by clinical indicators; inflammatory markers: CRP, ESR in the first hour and the disease activity level according to ASDAS-CRP and ASDAS-ESR in the first hour at the time of T2, T6 compared to T0 were statistically significant (p < 0.
05)).
After excluding the data of 2 patients with flare at T14, all the above-mentioned indicators improved, the difference was statistically significant with p < 0.
05.
Conclusion: Infliximab is effective in improving clinical symptoms, inflammatory markers and disease activity score in patients with Spondyloarthritis.
Key words: spondyloarthritis, Infliximab.
Related Results
Abstract 1809: The role of HyDIFFUZETM in co-formulation with subcutaneous infliximab
Abstract 1809: The role of HyDIFFUZETM in co-formulation with subcutaneous infliximab
Abstract
Background:
Recombinant human Hyaluronidase PH20 (rHuPH20) is an enzyme that degrades subcutaneous (SC) hyaluronan and ...
Relationship Between Trough Levels of Anti-Infliximab and Serum Biomarkers in Patients With Rheumatoid Arthritis
Relationship Between Trough Levels of Anti-Infliximab and Serum Biomarkers in Patients With Rheumatoid Arthritis
Rheumatoid arthritis is a chronic condition, characterized by the expression of antibody against self-antigens. Inflammatory cell of synovial tissues secreted numerous cytokines, i...
Inflammatory Bowel Disease Patients Are Frequently Nonadherent to Scheduled Induction and Maintenance Infliximab Therapy: A Canadian Cohort Study
Inflammatory Bowel Disease Patients Are Frequently Nonadherent to Scheduled Induction and Maintenance Infliximab Therapy: A Canadian Cohort Study
BACKGROUND: Adherence to maintenance medication regimens in inflammatory bowel disease patients has traditionally been poor. Although infliximab has demonstrated efficacy in induci...
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
Background/Objectives: Dose escalation has been commonly used to achieve and maintain response. We aimed to compare the outcomes of adalimumab or infliximab dose escalation in infl...
Dose Intensification with Infliximab in Patients with Rheumatoid Arthritis
Dose Intensification with Infliximab in Patients with Rheumatoid Arthritis
BACKGROUND
Infliximab, in combination with methotrexate, is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA). While there is a...
A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
BACKGROUND: Although infliximab is an effective therapy for inflammatory bowel disease (IBD), it is associated with dermatological events and infusion reactions. It is not known wh...
P012 Cross-specialty audit of Infliximab prescribing at the Great North Children’s Hospital (GNCH)
P012 Cross-specialty audit of Infliximab prescribing at the Great North Children’s Hospital (GNCH)
Abstract
Background/Aims
Infliximab is an anti-TNF biologic licensed for use in children and young people (CYP) with juvenile id...
Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication
Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication
Background:
The optimal use of infliximab depends on the measurement of trough levels with subsequent appropriate dose adjustment. With the introduction of biosimilars,...